Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus.
For the production of dengue-vaccine candidates, empty capsids, or virus-like particles (VLPs), of parvovirus B19 that carry dengue 2-specific epitopes were employed as antigen carriers. Two epitopes (comprising amino acids 352-368 and 386-397) of domain BIII of the envelope glycoprotein were chosen to produce recombinant B19 VLPs for immunization of BALB/c mice. Serum samples from immunized mice revealed that recombinant B19 VLPs elicited strong humoral immune responses. In summary, this B19 VLP-vaccine platform produced high (> or =2.0 x 10(5)) anti-dengue 2 titers and robust (< or =1 120) 50%-plaque-reduction neutralization test (PRNT(50)) titers, which effectively neutralized live dengue 2 virus in PRNT(50) assays.
Amexis
Georgios
G
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. amexis@nih.gov
Young
Neal S
NS
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000378:metabolism; D017951:Antigen Presentation / Q000502:physiology*; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D002460:Cell Line; D003716:Dengue Virus / Q000235:genetics / Q000276:immunology*; D000939:Epitopes / Q000235:genetics / Q000378:metabolism; D023061:Gene Order; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D016732:Parvovirus B19, Human / Q000235:genetics / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology*; D018411:Spodoptera
D000914:Antibodies, Viral; D036022:Capsid Proteins; D000939:Epitopes; D011994:Recombinant Proteins